Drugs and other chemicals frequently bind nonspecifically to the constituents of an in vitro incubation mixture, particularly the enzyme source [e.g., human liver microsomes (HLM)]. Correction for nonspecific binding (NSB) is essential for the accurate calculation of the kinetic parameters K m , Cl int , and K i . Many tyrosine kinase inhibitors (TKIs) are lipophilic organic bases that are nonionized at physiologic pH. Attempts to measure the NSB of several TKIs to HLM by equilibrium dialysis proved unsuccessful, presumably due to the limited aqueous solubility of these compounds. Thus, the addition of detergents to equilibrium dialysis samples was investigated as an approach to measure the NSB of TKIs. The binding of six validation set nonionized lipophilic bases (felodipine, isradipine, loratidine, midazolam, nifedipine, and pazopanib) to HLM (0.25 mg/ml) was shown to be unaffected by the addition of CHAPS (6 mM) to the dialysis medium. This approach was subsequently applied to measurement of the binding of axitinib, dabrafenib, erlotinib, gefitinib, ibrutinib, lapatinib, nilotinib, nintedanib, regorafenib, sorafenib, and trametinib to HLM (0.25 mg/ml). As with the validation set drugs, attainment of equilibrium was demonstrated in HLM-HLM and buffer-buffer control dialysis experiments. Values of the fraction unbound to HLM ranged from 0.14 (regorafenib and sorafenib) to 0.93 (nintedanib), and were generally consistent with the known physicochemical determinants of drug NSB. The extensive NSB of many TKIs to HLM underscores the importance of correction for TKI binding to HLM and, presumably, other enzyme sources present in in vitro incubation mixtures.
Introduction
In vitro approaches, using human liver microsomes (HLMs), human hepatocytes, or recombinant proteins as the enzyme source are used widely to characterize the kinetics of drug metabolism and drug-drug interaction potential (Houston, 1994; Obach, 1999; Rostami-Hodjegan and Tucker, 2007; Miners et al., 2010) . However, numerous drugs, especially lipophilic organic bases and neutral compounds, bind nonspecifically to the microsomal membrane. Importantly, nonspecific binding (NSB) reduces the concentration of the unbound drug in the incubation medium, resulting in overestimation of the measured kinetic constants K m (or S 50 ) and the inhibitor constant K i . Consequently, in vitro intrinsic clearance (determined as V max /K m ) and inhibitory drug-drug interaction potential (assessed as [I] /K i , where [I] is the inhibitor concentration) are both underpredicted (Obach, 1999; McLure et al., 2000; Margolis and Obach, 2003; Grime and Riley, 2006; Miners et al., 2006 Miners et al., , 2010 . Thus, it is now widely accepted that NSB should be accounted for when kinetic parameters are calculated from in vitro metabolism and inhibition studies.
Tyrosine kinase inhibitors (TKIs) are an emerging group of drugs used in the treatment of many forms of cancer and some other diseases (e.g., idiopathic pulmonary fibrosis). Typically, TKIs are lipophilic (log P values . 2.5) weak organic bases, which are frequently nonionized at physiologic pH. Thus, it might be expected that TKIs exhibit significant NSB. There have been numerous reports of the in vitro enzyme and inhibition kinetics of many TKIs. However, NSB appears to have been accounted for in the calculation of kinetic parameters in just one report (Kenny et al., 2012) .
Given the increasing number of TKIs entering clinical practice, we sought to characterize the drug-drug interaction potential of several drugs from this class. However, using lapatinib, pazopanib, regorafenib, and sorafenib as the model compounds, we encountered major problems determining NSB by equilibrium dialysis with HLM as the enzyme source. In particular, equilibrium was established in buffer-buffer and HLM-HLM controls for dialysis times ranging from 3 to 24 hours only with pazopanib, irrespective of whether we used conventional equilibrium dialysis (employing dialysis cells) or a commercial rapid equilibrium dialysis (RED) device. It has been reported that axitinib forms a supersaturated solution in buffers containing 0.5 or 1% dimethylsulfoxide (DMSO) (Reyner et al., 2013) , and we surmised a similar situation may occur more generally with TKIs during the course of equilibrium dialysis experiments. Thus, we explored the use of a number of detergents to retain TKIs in solution without disrupting microsomal binding. As reported here, inclusion of CHAPS in the dialysis medium allows determination of the NSB of weakly basic compounds, including TKIs. prepared according to the method of Bowalgaha et al. (2005) , were sourced from the human liver "bank" of the Department of Clinical Pharmacology of Flinders University. Approval was obtained from the Southern Adelaide Clinical Research Ethics Committee for the use of human liver tissue in drug disposition studies in vitro.
Equilibrium Dialysis. The NSB of drugs to HLM was measured by equilibrium dialysis. The equilibrium dialysis apparatus (Dianorm, Munich, Germany) comprised of Teflon dialysis cells of 1.2-ml capacity per side, separated by a Spectrapor #4 dialysis membrane (molecular mass cut off 12,000-14,000 Da; Spectrum Medical Industries Inc., Los Angeles, CA). The dialysis membrane was soaked overnight in phosphate buffer (PB) (0.1 M, pH 7.4) at 4°C prior to use in dialysis experiments. PB, a validation set or test drug (see Results and Discussion) dissolved in DMSO (0.01 ml; 1% v/v) and HLM (0.25 mg/ml), was loaded into one side of each dialysis cell, giving a total volume of 1 ml. Each of the drugs was diluted 1:100 upon addition to the dialysis cell to give the desired concentration. The other side of the dialysis cell contained PB and DMSO (1% v/v) . Dialysis experiments were performed in the presence and absence of detergent (see Results and Discussion) in each side of the dialysis cells (i.e., the same concentration of detergent was added to the donor and receiver compartments). The dialysis cell assembly was immersed in a water bath maintained at 37°C and rotated at 12 rpm. Equilibrium was achieved within 4-8 hours, although experiments were typically performed overnight. After dialysis, each side of the cell was unloaded by expelling the contents into a 5-ml glass tube. Control experiments, with either HLM (HLM-HLM) or PB (PB-PB) in both sides of the equilibrium dialysis cells (with or without detergent), were employed in each dialysis experiment to confirm attainment of equilibrium. The control experiments were performed at the lowest and highest drug concentration investigated (see Table 1 ). Attainment of equilibrium in HLM-HLM and PB-PB control experiments was deemed to occur for fraction unbound (fu mic ; see below) values in the range of 0.85-1.05. Equilibrium dialysis experiments at each drug (validation and test sets) concentration were performed in duplicate. Variances in duplicate fu mic values were invariably ,5%. The NSB of lapatinib, pazopanib, regorafenib, and sorafenib to HLM (0.25 mg/ml) was also investigated using a commercial RED device (Thermo Scientific, Rockford, IL) according to the protocol of the manufacturer. A suspension of HLM (0.3 ml), with or without the TKI (in 1% DMSO), was placed in the "donor" side, and PB (0.5 ml) and DMSO were placed in the "receiver" side. Following incubation, samples were treated as described below and analyzed by highperformance liquid chromatography (HPLC) (Supplemental Table 1 ).
High-Performance Liquid Chromatography. Concentrations of each drug present in the buffer and HLM compartments of dialysis cells (and RED devices) were measured by HPLC. For all drugs except amitriptyline, axitinib, chlorpromazine, nintedanib, and zidovudine, a 0.2-ml aliquot of sample from each cell of the dialysis apparatus was treated with an equal volume of ice cold 4% acetic acid in methanol (for compatibility with the mobile phase composition), vortex mixed, and then centrifuged at 5000g for 10 minutes. For the five drugs specified above, samples were treated with perchloric acid (70%, 2 ml). A 20-60 ml aliquot of the supernatant fraction was injected into the HPLC (Agilent 1100 series instrument; Agilent Technologies, Sydney, Australia), which was fitted with a Waters NovaPak C18 analytical column (150 Â 3.9 mm (i.d.), 5-mm particle size; Waters Corporation, Milford, MA). Chromatography conditions are shown in Supplemental Table 1 . Chromatograms of all analytes were free from interference under the conditions employed. Concentrations of validation set compounds and TKIs were determined by reference to standard curves prepared for each compound over the ranges of 1-100 mM (non-TKI validation set compounds) and 0.1-2 mM (TKIs). The fraction unbound to HLM (fu mic ) was calculated as the concentration of drug in the buffer cell divided by the concentration of drug in the cell containing HLM.
Computational Calculation of Log P, Percent Ionization, and fu mic . Log P values were obtained using four algorithms. SMILES strings of compounds were obtained from the Pubchem server (https://pubchem.ncbi.nlm.nih.gov/) and then used to generate the two-dimensional structures of molecules in MarvinSketch. The two-dimensional structures were used for calculating log P values from Marvin (Marvin 14.12.8.0, ChemAxon, http://www.chemaxon. com; physico-chemical property predictors of the Marvin calculator plugin), whereas AlogP2.1 (http://www.vcclab.org/web/alogps/) and XlogP3 (http://www. sioc-ccbg.ac.cn/software/xlogp3/) values were calculated from the respective webservers using SMILES strings as the input. Log P values were additionally obtained from ACD/Laboratories ChemSpider (http://www.chemspider.com/) by a chemical name search. The pKa of each molecule was calculated at pH 7.4 using the physicochemical property predictors of the Marvin calculator plugins. The values of fu mic were predicted using the SimCYP ADME calculator (SimCYP prediction tools) based on the assigned compound type (acid/base/neutral) and calculated log P and pKa and using equations based on log P given by Austin et al. (2002) (viz. eq. 11) and Hallifax and Houston (2006) . a Predicted values calculated using the equation fu inc = 1/C · 10 0.56 log P 2 1.41 + 1. b Predicted values calculated using the equation fu inc = 1/1 + C · 10 0.072(log P)2 + 0.067 × log P 2 1.126 . dmd.aspetjournals.org
Results and Discussion
As noted in the Introduction, TKIs are typically lipophilic organic bases that are neutral or partially ionized at pH 7.4. The aqueous solubility of TKIs is poor, although, at least at relatively low concentrations (,100 mM), solubilization is achieved in in vitro incubations containing HLM and DMSO (1% w/v). Initial studies of the NSB of lapatinib, pazopanib, regorafenib, and sorafenib to HLM, using either equilibrium dialysis cells or a commercial RED device, demonstrated that equilibrium was established in buffer-buffer and HLM-HLM (0.25 mg/ml) controls only for pazopanib. Increasing the concentration of DMSO present in the dialysis medium to 2% or using other organic solvents (acetonitrile, methanol, and 0.95% acetonitrile plus 0.05% DMSO, as reported by Kenny et al. (2012) ] did not result in the attainment of equilibrium in control experiments with lapatinib, regorafinib, and sorafenib. The mean (6 S.D.) fu mic of pazopanib obtained by conventional equilibrium dialysis (in the presence of 1% DMSO) was 0.75 6 0.03 for five concentrations in the range of 0.1-2 mM (Table 1) . Similarly, the use of ultracentrifugation with lapatinib, regorafinib, and sorafenib resulted in almost immeasurable concentrations in the reservoir compartment and low recoveries (,50%).
Thus, we explored the use of the detergents Brij-58, CHAPS, and Triton X-100 to aid the solubilization of TKIs in NSB experiments. Each of the detergents used differ in terms of physicochemical properties and critical micelle concentration (CMC). Since detergents may disrupt the microsomal membrane and hence potentially NSB, equilibrium dialysis experiments were performed with eight validation set basic drugs, for which attainment of equilibrium could be demonstrated in buffer-buffer and HLM-HLM (0.25 mg/ml) controls in the absence of detergent. Pazopanib (see above), felodipine, isradipine, loratidine, midazolam, and nifedipine are weak organic bases that are nonionized in phosphate buffer at pH 7.4, whereas amitriptyline and chlorpromazine are lipophilic bases that are essentially completely ionized at pH 7.4. Zidovudine, a zwitterionic compound that is extensively ionized and known not to bind nonspecifically to HLM (Uchaipichat et al., 2006) , served as a "negative" control. Table 1 lists the percentage of ionization and the calculated log P for each of the control drugs and TKIs investigated here, whereas Supplemental Fig. 1 shows the structures of the validation set drugs and TKIs. It is noteworthy that calculated log P varied by as much as a factor of 2 (i.e., 2 log orders) using the four algorithms employed here (Table 1) . Thus, Table 1 gives the range (lowest to highest) of the calculated log P values.
NSB of the validation set drugs amitriptyline, chlorpromazine, felodipine, isradipine, loratidine, midazolam, nifedipine, and zidovudine was measured in duplicate at five concentrations in the range of 1-100 mM, whereas the binding of all TKIs (including pazopanib) was measured at five concentrations in the range of 0.1-2 mM, which we have found to be relevant for inhibition studies (unpublished data). Binding of each of the validation set drugs was independent of concentration in the absence of detergent. Brij-58 (0.007 mM; CMC, 0.007-0.07 mM) disrupted the binding of all eight basic drugs; fu mic values were higher with added detergent compared with the absence of detergent (data not shown). Despite the attainment of equilibrium in buffer-buffer and HLM-HLM controls in NSB experiments conducted in the presence of Triton X-100 (CMC, 0.2-0.9 mM), the recoveries of each compound were low (,50%). By contrast, the presence of CHAPS (6 mM; CMC, 6-10 mM) had no effect on the binding of pazopanib, felodipine, isradipine, loratidine, midazolam, and nifedipine to HLM, although binding of the fully charged bases amitriptyline and chlorpromazine to HLM was disrupted (Table 1) . No binding of zidovudine was observed in the absence or presence of CHAPS. Importantly, recoveries of all nine drugs from the equilibrium dialysis cells were acceptable (.70%) and attainment of equilibrium (fu mic values of 0.85-1.05) was demonstrated for buffer-buffer and HLM-HLM control experiments.
Based on these data, the microsomal binding of eight TKIs (axitinib, erlotinib, gefitinib, ibrutinib, nilotinib, regorafenib, sorafenib, and trametinib) that are completely or largely unionized at pH 7.4 and three TKIs that are partially ionized (39-64%) at pH 7.4 (dabrafenib, lapatinib, and nintedanib) was characterized in the presence of CHAPS (6 mM) ( Table 1) . NSB of the TKIs was concentration independent over the range of 0.1-2 mM. Measured fu mic values ranged from 0.14 (regorafenib and sorafenib) to 0.93 (nintedanib). Recoveries of each of the TKIs from equilibrium dialysis cells were .70%, and attainment of equilibrium was demonstrated in buffer-buffer and HLM-HLM control experiments (fu mic values of 0.85-1.05). Subsequent experiments demonstrated that equilibrium was also attained in dialysis experiments with the neutral TKI erlotinib and the partially charged dabrafenib in the absence of CHAPS; fu mic values generated in the presence and absence of detergent were essentially identical (Table 1) .
There was no clear relationship between the extent of ionization at pH 7.4 and fu mic for the drugs investigated here. While the two most extensively charged compounds (dabrafenib and nintedanib) exhibited low NSB, the moderately ionized (38%) lapatinib bound extensively to HLM. Although the three highest binding TKIs (lapatinib, regorafenib, and sorafenib) have high log P values (4.2-5.2), the binding of axitinib (log P of 4.2) was comparatively low. Thus, log P is clearly not the sole determinant of extensive NSB of TKIs to HLM. We and others have shown previously that NSB is generally highest for lipophilic organic bases with molecular masses .200 Da (Austin et al., 2002; Hallifax and Houston, 2006; Sykes et al., 2006; McLure et al., 2011) . However, other physicochemical properties also influence the degree of NSB. These include the presence of halogen atoms (especially the trifluoromethyl group), polar surface area, charge distribution, and number of hydrogen bond acceptors/donors [summarized by McLure et al. (2011) ]. Not only does the addition of fluorine or the trifluoromethyl groups to an aryl ring or adjacent to a heteroatomcontaining functional group increase lipophilicity (Hagmann, 2008) , but halogenation of drugs is more generally known to enhance drug membrane binding and permeation. The importance of the trifluoromethyl group in particular has been highlighted in this regard (Gerebtzoff et al., 2004) . With respect to the TKIs investigated here, nilotinib, regorafenib, and sorafenib all possess a trifluoromethyl group (Supplemental Fig. 1) . However, the two TKIs that bind most extensively to HLM, sorafenib and regorafenib, additionally contain one and two additional halogen atoms, respectively. Kenny et al. (2012) reported the NSB of a number of TKIs to HLM (0.6 mg/ml) using a commercial RED device. The TKIs investigated included several of those studied here: lapatinib, nilotinib, pazopanib, and sorafenib. As noted previously, in our hands, only pazopanib attained equilibrium in HLM-HLM and buffer-buffer controls using a RED device and conventional equilibrium dialysis. The previous study did not report data for HLM-HLM and buffer-buffer controls. Since different HLM concentrations were employed in the two studies, the results are not directly comparable. However, the rank order of binding reported by Kenny et al. (lapatinib . nilotinib . pazopanib . sorafenib) differs markedly from that found here.
The SimCYP ADME calculator and equations published by Austin et al. (2002) and Hallifax and Houston (2006) that were used here to predict fu mic values take into account only log P and charge state/ ionization. The predicted fu mic values are shown in Table 1 as a range since the calculated log P values differed among the algorithms. Indeed, as highlighted previously, the calculated log P values surprisingly differed by as much as a factor of 2. Despite using a range of log P values for the calculation of fu mic , this parameter was generally underpredicted for the most highly bound compounds using the SimCYP calculator and the equation published by Hallifax and Houston. Although the fu mic values predicted for the highly bound compounds regrofenib and sorafenib using the equation of Austin et al. spanned the experimentally determined fu mic , this equation tended to overpredict the binding of other TKIs. No single algorithm for calculated log P performed consistently well for predicting fu mic (data not shown). More generally, the choice of log P algorithm used for the prediction of NSB and other parameters warrants further investigation. Available evidence demonstrates that NSB, particularly of lipophilic basic drugs, arises largely from the partitioning of drugs into phospholipid membranes (Margolis and Obach, 2003; Nussio et al., 2007; McLure et al., 2011; Nagar and Korzekwa, 2012) . Neutron diffraction studies with the charged lipophilic base propranolol showed that that the lipophilic naphthalene moiety partitions into the lipid bilayer, whereas the charged amine group apparently associates with the phospholipid head group (Herbette et al., 1983) . CHAPS was selected as the detergent for the solubilization of TKIs here because it retained all compounds in an aqueous solution and, since the concentration employed in this work (6 mM) is at the lower end of the CMC range, it was expected not to affect dialysis. This was confirmed by the attainment of equilibrium in control experiments. Moreover, CHAPS (6 mM) was shown to have no effect on the NSB of the six neutral basic validation set drugs: felodipine, isradipine, loratidine, midazolam, nifedipine, and pazopanib. Later experiments further demonstrated that CHAPS (6 mM) is similarly without effect on the NSB of erlotinib and the partially charged dabrafenib (Table 1) . CHAPS concentrations below 6 mM (viz. 2 and 4 mM) appeared to give incomplete solubilization of the more lipophilic TKIs, whereas fu mic values of representative TKIs and "control" drugs (felodipine, lapatinib, pazopanib, regorafenib, and sorafenib) were shown to increase as the CHAPS concentration was increased to 10 mM (data not shown). The latter observation appears to be consistent with the known effects of CHAPS on membrane structure. At low concentrations, detergent molecules tend only bind to the surface of the membrane, but as the CHAPS concentration increases, the membrane bilayer becomes disrupted (Kalipatnapu and Chattopadhyay, 2005) . Such a model further explains why CHAPS disrupts the binding of the fully charged amitriptyline and chlorpromazine to HLM.
In summary, conventional equilibrium dialysis performed in the presence of CHAPS permits measurement of the NSB of neutral TKIs to HLM. NSB data were also generated for partially charged TKIs, which appeared consistent with the physicochemical properties of these compounds (and confirmed in the case of dabrafenib). It is emphasized that the method has been developed specifically for uncharged and weakly charged lipophilic organic bases, and it is unlikely to be applicable to other chemical classes. Moreover, experiments were performed at a single HLM concentration (0.25 mg/ml) and further method optimization will be required for other HLM concentrations. Since detergents are known to affect cytochrome P450 and UDPglucuronosyltransferase enzyme activities in a concentration-dependent and variable manner, the addition of CHAPS to microsomal incubations is generally not recommended. However, as noted earlier, the solubility of relatively low concentrations of TKIs in incubations of HLM containing DMSO appears to be acceptable. NSB has generally been ignored in previous in vitro kinetic and inhibition studies of TKIs. The substantial microsomal binding of many of the TKIs investigated here indicates that the K m and K i values will be significantly overestimated if NSB is not accounted for, which in turn impacts the accuracy of in vivo intrinsic clearance values and the drug-drug interaction potential predicted using in vitro-in vivo extrapolation approaches.
